XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1
OTHER FINANCIAL INFORMATION (Tables)
 6 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Prepaid Expense and Other Current Assets
Prepaid expense and other current assets were comprised of the following (in thousands):
AS OFAS OF
JUNE 30, 2024DECEMBER 31, 2023
Clinical trials (1)
$5,910 $5,409 
Clinical drug substance and product manufacturing (2)
4,931 9,888 
Licenses1,116 728 
Outside research and development services (3)
887 265 
Other966 366 
Prepaid expense and other current assets$13,810 $16,656 
(1) Relates primarily to the Company’s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company’s therapeutics. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
(2) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
(3) Relates to the Company’s usage of third-parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
Schedule of Property and Equipment
Property and equipment, net were comprised of the following (in thousands):
AS OFAS OF
JUNE 30, 2024DECEMBER 31, 2023
Machinery and equipment$9,074 $8,480 
Furniture, fixtures, and other556 540 
Leasehold improvements795 441 
Computer software3,832 53 
Construction in process (1)
824 3,592 
Total property and equipment15,081 13,106 
Less: accumulated depreciation and amortization(7,476)(6,687)
Property and equipment, net$7,605 $6,419 
(1) As of December 31, 2023, consists of renovations to the Company’s office space and software not yet placed in service.

Depreciation and amortization expense for the three and six months ended June 30, 2024 and June 30, 2023 consisted of the following (in thousands):
THREE MONTHS ENDED
JUNE 30,		SIX MONTHS ENDED
JUNE 30,
2024202320242023
Research and development$374 $242 $631 $479 
General and administrative101 53 205 110 
Total depreciation and amortization expense$475 $295 $836 $589 
Schedule of Accrued Expenses
Accrued expenses were comprised of the following (in thousands):
AS OFAS OF
JUNE 30, 2024DECEMBER 31, 2023
Clinical trials (1)
$12,215 $9,224 
Clinical drug substance and product manufacturing (2)
4,538 22,805 
Other outside research and development (3)
1,217 1,129 
Compensation-related4,508 6,506 
Professional fees959 780 
Interest expense— 2,348 
Other423 503 
Accrued expenses$23,860 $43,295 
(1) Relates primarily to the Company’s usage of third-party CROs for management of clinical trials. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
(2) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
(3) Relates to the Company’s usage of third-parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.